BioSpace News Archive

Opinion

Washington’s Policy Shifts Are Driving Capital Away From Life-Saving Research

Drug pricing, budget cuts, tariffs and other shifts under the Trump administration undermine the biopharma and healthcare ecosystem.

June 24, 2025

·

4 min read

·

John Stanford

Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie

Rare diseases

FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent

Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway proposed by FDA Commissioner Marty Makary. They acknowledged, however, that creative thinking is required to enable more treatments for patients with ultrarare diseases.

June 24, 2025

·

3 min read

·

Heather McKenzie

Weight loss

Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy

Eli Lilly’s bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, marketed by rival Novo Nordisk as Wegovy. BMO Capital Markets called the data “impressive” while raising concerns about the antibody’s safety profile.

June 24, 2025

·

2 min read

·

Tristan Manalac

Passenger plane takes off from runway. Air transport, vector illustration

Deals

Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal

In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.

June 24, 2025

·

1 min read

·

Annalee Armstrong

Illustration showing line of people leaving, standing on top of hand pointing their way out

Layoffs

Leap Slashes 75% of Workforce, Explores Strategic Options

In addition to cutting most of its staff, including two C-suite executives, Leap Therapeutics is winding down research and development activities and considering a sale or partnership opportunities.

June 24, 2025

·

1 min read

·

Angela Gabriel

Artificial intelligence

In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

June 24, 2025

·

2 min read

·

Tristan Manalac

Illustration showing scientist climbing up DNA spiral staircase

Gene therapy

Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C. Wainwright. Sangamo plans to use pivotal Phase I/II data to build an accelerated approval case for the asset.

June 24, 2025

·

3 min read

·

Tristan Manalac

HHS Secretary Robert F. Kennedy Jr. appears before the Energy and Commerce committee on Tuesday.

Government

‘People Are Going to Die’: HHS Hearing With Kennedy Turns Into Shouting Match

With much to cover, Democrats tackled Kennedy’s MAHA report; the firing of all members of the CDC’s ACIP committee; and much more. Little was accomplished, as Kennedy demurred and members of Congress accused him of risking American lives.

June 24, 2025

·

4 min read

·

Annalee Armstrong

Press Releases

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

June 24, 2025

·

17 min read

Press Releases

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

June 24, 2025

·

2 min read